# Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

> **NCT06763965** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Beijing Bio-Targeting Therapeutics Technology Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent High-grade Glioma

## Interventions

- **BIOLOGICAL:** BioTTT001 injection

## Key facts

- **NCT ID:** NCT06763965
- **Lead sponsor:** Beijing Bio-Targeting Therapeutics Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-11-26
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06763965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06763965, "Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06763965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*